Summary
Global
Markets Direct's, 'Niemann Pick C1 Like Protein 1 (NPC1L1) - Pipeline Review,
H1 2016', provides in depth analysis on Niemann Pick C1 Like Protein 1 (NPC1L1)
targeted pipeline therapeutics.
The
report provides comprehensive information on the Niemann Pick C1 Like Protein 1
(NPC1L1), targeted therapeutics, complete with analysis by indications, stage
of development, mechanism of action (MoA), route of administration (RoA) and
molecule type. The report also covers the descriptive pharmacological action of
the therapeutics, its complete research and development history and latest news
and press releases. Additionally, the report provides an overview of key
players involved in Niemann Pick C1 Like Protein 1 (NPC1L1) targeted
therapeutics development and features dormant and discontinued projects.
Read Complete
Report with TOC @ http://www.radiantinsights.com/research/niemann-pick-c1-like-protein-1-npc1l1-pipeline-review-h1-2016
Global
Markets Direct's report features investigational drugs from across globe covering
over 20 therapy areas and nearly 3,000 indications. The report is built using
data and information sourced from Global Markets Direct's proprietary
databases, company/university websites, clinical trial registries, conferences,
SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources. Drug
profiles featured in the report undergoes periodic review following a stringent
set of processes to ensure that all the profiles are updated with the latest
set of information. Additionally, various dynamic tracking processes ensure
that the most recent developments are captured on a real time basis.
No comments:
Post a Comment